Faraday Future to Host Investor Presentation Webcast
LOS ANGELES–(BUSINESS WIRE)–Faraday Future Intelligent Electric Inc. (NASDAQ: FFIE) (“Faraday Future”, “FF” or “Company”), a…
News
Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer
ELI-002 2P is an investigational therapeutic cancer vaccine targeting solid tumors driven by G12D and…
Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer
ELI-002 2P is an investigational therapeutic cancer vaccine targeting solid tumors driven by G12D and…
Mydecine Innovations Group Announces Expected U.K. Dual Listing Admission Date
VANCOUVER, British Columbia, Sept. 27, 2023 (GLOBE NEWSWIRE) — Mydecine Innovations Group Inc. (“Mydecine” or…
Mydecine Innovations Group Announces Expected U.K. Dual Listing Admission Date
VANCOUVER, British Columbia, Sept. 27, 2023 (GLOBE NEWSWIRE) — Mydecine Innovations Group Inc. (“Mydecine” or…
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage…
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage…
Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS –…
Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS –…
Better Choice Company Receives NYSE American Notice
TAMPA, Fla., Sept. 27, 2023 (GLOBE NEWSWIRE) — Better Choice Company, Inc. (NYSE American: BTTR)…
Better Choice Company Receives NYSE American Notice
TAMPA, Fla., Sept. 27, 2023 (GLOBE NEWSWIRE) — Better Choice Company, Inc. (NYSE American: BTTR)…
PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society and the World Congress of Neurology
BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) — PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company…
PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society and the World Congress of Neurology
BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) — PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company…
Supernus Pharmaceuticals Announces Webcast of R&D Day to be Held on October 18, 2023 in New York City
ROCKVILLE, Md., Sept. 27, 2023 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical…
Supernus Pharmaceuticals Announces Webcast of R&D Day to be Held on October 18, 2023 in New York City
ROCKVILLE, Md., Sept. 27, 2023 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical…
Praxis Precision Medicines To Host Hybrid R&D Day on Monday, October 2, 2023
BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage…
QIAGEN reports progress toward achieving Environmental, Social and Governance goals in 2022 Sustainability Report
Progress on Environment, Social and Governance (ESG) goals reflected in QIAGEN securing a „Prime“ rating…
23andMe Announces Poster Presentations on 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2023 Annual Meeting
23andMe to present data on efficacy and safety and dose selection for the ongoing 23ME-00610…
Sagimet Biosciences Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by Its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent Glioblastoma
SAN MATEO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Nasdaq: SGMT), a…
Cadence Digital and Custom/Analog Design Flows Achieve the Latest TSMC N2 Certification
Highlights: Cadence digital full flow includes key new technologies, including a high-accuracy and massively scalable…